IMUC (EOM Pharmaceutical Holdings) Non Operating Income: $0.00 Mil (TTM As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Non Operating Income?

EOM Pharmaceutical Holdings IMUC Non Operating Income is $0.00 Mil as of Jun. 2018.

Non Operating Income is income or expense that comes from miscellaneous sources. EOM Pharmaceutical Holdings's Non Operating Income for the three months ended in Jun. 2018 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2018 was $0.00 Mil.

EOM Pharmaceutical Holdings Non Operating Income Related Terms

EOM Pharmaceutical Holdings Non Operating Income Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Non Operating Income Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.53 2.93 3.81 7.72

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.72 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.00 Mil mean?
EOM Pharmaceutical Holdings (IMUC) has a Non Operating Income of $0.00 Mil as of Jun. 2018. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Non Operating Income too high?
EOM Pharmaceutical Holdings' current Non Operating Income is $0.00 Mil.
How does EOM Pharmaceutical Holdings' Non Operating Income compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Non Operating Income of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Non Operating Income is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Non Operating Income of $0.00 Mil. The current Non Operating Income is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Non Operating Income is $0.00 Mil as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.